mAbs

Views & Analysis

Artificial Intelligence for better antibody drugs: ready for...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

Views & Analysis

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

How cell and gene therapies are transforming pharma deal-mak...

After decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to deliver with the first generation of promising new cel

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks